Rising attention to research and development of lung cancer screening and diagnosis tools is one of the key factors propelling market expansion. In April 2020, for instance, scientists at the Massachusetts Institute of Technology (MIT) created a nanoparticle-based strategy that enables the early detection of lung cancer using a straightforward urine test. Through the interaction of peptide-coated nanoparticles with disease-associated proteases in the tumour microenvironment, the method can identify biomarkers. The urine test was shown to be capable of detecting tumours as tiny as 2.8 mm in two separate lung cancer mice models. The objective is that this kind of noninvasive diagnostic will help find more tumours in the early stages of the disease and lessen the amount of false positives associated with a current test method.
The market for lung cancer diagnostic and screening is anticipated to reach a value of US$ 1,931.0 million in 2020 and grow at a CAGR of 7.8% from 2021 to 2028.
1. Abbott: Abbott produces and sells branded generic pharmaceuticals, adult and paediatric nutritional items, diagnostic tools, and testing kits. Pacemakers, implanted cardioverter defibrillators, neuromodulation tools, coronary stents, catheters, baby formula, adult dietary liquids, molecular diagnostic platforms, immunoassays, and point-of-care diagnostic tools are among the products. Built in 1888. American headquarters in North Chicago. Recent Acquisitions: Cephea Valve Technologies (Jan 2019), JETi (Sep 2021), Cardiovascular Systems (Feb 2023).
2. Thermo Fischer Scientific: Thermo Fisher Scientific sells reagents for life sciences, laboratory supplies, and equipment for diagnostics. Founded 1956. United States headquarters.
3. QIAGEN: DNA, RNA, and proteins can be extracted, purified, amplified, and interpreted using Qiagen's unique sample and assay technologies. The company's sales are split roughly evenly between molecular diagnostics and applications in the life sciences. In 2021, the Americas will generate 45% of the company's revenue, followed by EMEA (36%), and Asia-Pacific (19%). created in 1984. head office in Germany.
4. Quest Diagnostics Incorporated: Established in 1967. In the United States, Quest Diagnostics is a preeminent independent provider of diagnostic testing, data, and services. Over 2,300 patient care centres across the country, as well as numerous doctors' offices and hospitals, collect specimens for the company's clinical testing, anatomic pathology, esoteric testing, and substance addiction testing departments. These departments account for over 95% of the company's revenue.
5. NeoGenomics: A network of American genetic testing facilities for cancer as well as a facility in Switzerland are run by NeoGenomics Inc. The business is divided into two divisions: Clinical Services and Pharma Services. Cytogenetics, Fluorescence In-Situ Hybridization, Flow Cytometry, Immunohistochemistry, Molecular Testing, and Pathology Consultation are among the several genetic and molecular testing services it provides. Clinical Services are the source of the business's revenue.
6. F. Hoffmann-La Roche Ltd: Tasmar's rights to production, marketing, and distribution in the United States and a few other non-European Union areas. Parkinson's illness is managed with the medication tasmar. United States headquarters. For $449 million, Roche buys the biotech company Inflazome.
7. Sanofi: Sanofi S.A. is a multinational pharmaceutical company that engages in the research and development, of pharmacological products, in the prescription market. The firm cover therapeutic areas like Cardiovascular, central nervous system, diabetes, internal medicine. The company was founded in 973 and the headquarters are located in Paris, France. Products manufactured include Medications, Genetic drugs, Vaccines, Animal Health, etc. December, 2022 Sanofi expanded its collaboration with Innate Pharma, with Sanofi licensing a natural killer (NK) cell nagger program targeting B7H3 from Innate’s ANKET platform.
*Definition: Lung cancer is diagnosed through imaging tools, including computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET) scans.
